The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma

Clinical Advances in Hematology and Oncology

Volumn 8, Issue 2, 2010, Pages 108-115

  Tewari, Krishnansu Sujata ^a   Monk, Bradley J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cervical cancer; Nonplatinum doublets; Platinum resistance

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOSPORIN A; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; TOPOTECAN; VINBLASTINE;

ADVANCED CANCER; ANEMIA; BLOOD TOXICITY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG POTENTIATION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HUMAN; HYSTERECTOMY; LEUKOPENIA; METASTASIS; MONOTHERAPY; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; OVERALL SURVIVAL; PREOPERATIVE TREATMENT; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIOSENSITIZATION; RECURRENCE RISK; RECURRENT CANCER; REVIEW; SEPSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG SYNERGISM; FEMALE; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RADIATION-SENSITIZING AGENTS; SALVAGE THERAPY; TOPOTECAN; UTERINE CERVICAL NEOPLASMS;

EID: 77749237017     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Monk BJ, Tewari KS. Invasive cervical cancer, In DiSaia PJ, Creasmant WT, eds. Clinical Gynecologic Oncology. 7th ed. Philadelphia, PA: Mosby Publishers; 2007.
2. Jemal A, Siegel R, Ward E, Hao Yongping, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
3. Monk BJ, Tewari KS, Koh WJ. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Oncol. 2007; 27:2952-2965.
4. Peters III WA, Liu PY, Barrett II RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-1613.
5. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-1161.
6. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137-1143.
7. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17:1339-1348.
8. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144-1153.
9. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005;3:CD002225.
10. Tewari KS, Monk BJ. Gynecologic Oncology Group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep. 2005;7:419-434.
11. Bonomi P, Blessing JA, Stehman FB, DiSaia PJ, Walton L, Major FJ. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol. 1985;3:1079-1085.
12. Thigpen JT, Blessing JA, DiSaia PJ, Fowler WC Jr, Hatch KD. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1989;32:198-202.
13. McGuire WP III, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1989;7:1462-1468.
14. Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15:165-171.
15. Bloss JD, Blessing JA, Behrens BC, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2002;20:1832-1837.
16. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113-3119.
17. Long HJ 3rd, Bundy BN, Grendys EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626-4633.
18. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatincontaining doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649-4655.
19. McGuire WP, Blessing JA, Moore D, Lentz SS, Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1996;14:792-795.
20. Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1999;17:2676-2680.
21. Long HJ 3rd, Cross WG, Wieand HS, et al. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina. Gynecol Oncol. 1995;57:235-239.
22. Fiorica J, Holloway R, Ndubisi B, et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol Oncol. 2002;85:89-94.
23. Long HJ 3rd, Monk BJ, Huang H. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;100:537-543.
24. Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol. 2009;36:170-180.
25. Stordal B, Pavlakis N, Davey R. Oxaliplatin for the treatment of cisplatinresistant cancer: a systematic review. Cancer Treatment Reviews. 2007;33:347-357.
26. Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez A, et al. Induction chemotherapy with gemcitabine and oxaliplatin for locally advanced cervical carcinoma. Am J Clin Oncol. 2003;26:22-25.
27. Fracasso PM, Blessing JA, Wolf J, Rocereto TF, Berek JS, Waggoner S. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;90:177-180.
28. Takara K, Sakaeda T, Yagami T, et al. Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull. 2002;25:771-778.
29. Ohmichi M, Hayakawa J, Tasaka K, Kurachi H, Murata Y. Mechanisms of platinum drug resistance. Trends Pharmacol Sciences. 2005;26:113-116.
30. Nagourney RA, Link JS, Blitzer JB, Forsthoff C, Evans SS. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J Clin Oncol. 2000;18:2245-2249.
31. Nagourney RA, Brewer CA, Radecki S, Disaia P. Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer subjects. Gynecol Oncol. 2003;88:35-39.
32. Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum and multidrug-resistant ovarian and peritoneal carcinoma. Gynecol Oncol. 2003;88: 17-21.
33. Brewer CA, Blessing JA, Nagourney RA, McMeekin DS, Lele S, Zweizig SL. Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;100:385-388.
34. Symonds R, Davidson S, Chan S, Reed N, McMahon T, Paul J. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second-line chemotherapy in cervical cancer. J Clin Oncol (ASCO Annual Meeting Abstracts). 2007;25:Abstract 5548.
35. Miller DS, Blessing JA, Bodurka DC, Bonebrake AJ, Schorge JO. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2008;110:65-70.
36. Lorusso D, Ferrandina G, Pignata S, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol. 2010;21:61-66.
37. Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol. 2001;48:188-196.
38. Tiersten AD, Selleck MJ, Hershman DL, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol. 2004;92:635-638.
39. Thiel F (study chair). AGO protocol IFG-01-0106. A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan to those of cisplatin and topotecan for treatment of patients with recurrent or persistent cervical cancer.
40. Tewari KS (study chair). Protocol GOG-0240. A randomized phase 3 trial of cisplatin plus paclitaxel with and without NCI-supplied bevacizumab (NSC #704865 IND #7921) versus the non-platinum doublet, topotecan plus paclitaxel, with and without NCI supplied bevacizumab, in stage IVB, recurrent or persistent carcinoma of the cervix. www.gog.org. Accessed April 2009.
41. Tewari KS. Expert panel: Patients with metastatic/recurrent cervical cancer should be treated with cisplatin plus paclitaxel. Clinical Ovarian Cancer. 2010 (in press).
42. Moore DH, Tian C, Monk BJ, Long HJ, Omura GA, Bloss JD. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116:44-49.
43. Monk BJ, Sill MW, Burger RA, Gray HJ, Buekers TE, Roman LD. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:1069-1074.
44. Takano M, Kikuchi Y, Kita T, et al. Complete remission of metastatic and relapsed uterine cervical cancers using weekly administration of bevacizumab and paclitaxel/carboplatin. Onkologie. 2009;32:595-597.
45. Tewari KS, Monk BJ. Beyond platinum for metastatic and recurrent carcinoma of the cervix. Onkologie. 2009;32:552-554.